INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results

INmune Bio (NASDAQ:INMB) released its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.14, Zacks reports.

INmune Bio Price Performance

Shares of NASDAQ INMB traded down $0.27 on Friday, hitting $7.14. The company’s stock had a trading volume of 61,057 shares, compared to its average volume of 241,182. The stock has a 50 day moving average of $8.39 and a 200-day moving average of $6.37. INmune Bio has a 12-month low of $4.32 and a 12-month high of $12.72. The company has a market capitalization of $189.86 million, a price-to-earnings ratio of -3.25 and a beta of 1.93.

Analyst Upgrades and Downgrades

INMB has been the topic of several analyst reports. RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Maxim Group raised their price target on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Scotiabank increased their price objective on INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, February 11th. Finally, Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.